Abstract
Allogeneic hematopoietic stem cell transplant, once considered too risky for older patients with myelodysplastic syndrome (MDS), is associated with significantly improved survival for those with matched donors relative to non‐transplant treatment. New findings from the Blood and Marrow Transplant Clinical Trials Network suggest a revised standard of care for older patients with MDS.